臺灣博碩士論文加值系統

　　三陰性乳腺癌 (TNBC) 由於缺乏雌激素受體(ER)、黃體素受體 (PR) 與第二型人類表皮生長因子受體 2 (HER-2) 表達，被認為是乳腺癌表型中最難治療之類型。近十年來研究重點在於找尋治療靶點，如將 TNBC 細胞逆轉成 ER陽性乳癌細胞。
　　本研究透過利用 shRNA MZF-160-72 抑制 MZF-1B 會增進 IGF-1R 與ERα 之表達。IGF-1R可透過 p38 MAPK signaling pathway 控制 ERα 之表達，而IGF-1R則是受到 MZF-1B在轉錄階段下之直接調控。然而在抗癌藥物 (Cisplatin、Tamoxifen citrate 與 Letrozole)敏感性之實驗結果發現，經抑制 MZF-1B 之 TNBC 細胞與原始TNBC細胞之間之抗癌藥物敏感性並無顯著差異。因此未來若可克服抗癌藥物敏感性實驗結果之問題，此些發現可為 TNBC 之治療提供新的策略方向。

　　Triple-negative breast cancer (TNBC) is considered as the most difficult therapeutic phenotypes of breast cancer due to the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expressions. Over the last decade, the current focus of treatment research is hunting for therapeutic targets, as TNBC cells reversal to ER-positive breast cancer cells.
　　This research discover that when down-regulated MZF-1B by shRNA MZF-160-72 transfection, the IGF-1R and ERα expression were increased. The expression of ERα was controlled by IGF-1R through p38 MAPK signaling pathway, while IGF-1R was regulated directly by MZF-1B in a transcriptional level. Whereas, the anti-cancer drugs (cisplatin, tamoxifen citrate and letrozole) sensitivity test showed that there were not significant difference in the MZF-1B-down-regulated-and original- TNBC cells. Therefore, if the result of anti-cancer drugs sensitivity can be overcome in the future, these findings will provide a new strategy for TNBC therapy.

致謝 --------------------------------------------------------------------------------------------- 1
中文摘要 --------------------------------------------------------------------------------------- 3
英文摘要 --------------------------------------------------------------------------------------- 4
緒論
　　一、癌症 (Cancer)
　　　　1-1 影響程度 ---------------------------------------------------------------------- 5
　　　　1-2 形成過程與特性 ------------------------------------------------------------- 6
　　二、乳癌 (Breast Cancer)
　　　　2-1 影響程度 ---------------------------------------------------------------------- 8
　　　　2-2 乳癌分期與種類 ------------------------------------------------------------- 9
　　　　2-3 三陰性乳腺癌 -------------------------------------------------------------- 10
　　　　2-4 治療乳腺癌之藥物 -------------------------------------------------------- 11
　　三、生長因子
　　　　3-1 MZF-1 ------------------------------------------------------------------------- 12
　　　　3-2 IGF-1 -------------------------------------------------------------------------- 12
　　　　3-3 ER ------------------------------------------------------------------------------ 13
研究動機 -------------------------------------------------------------------------------------- 14
實驗材料與器材 ----------------------------------------------------------------------------- 16
實驗方法
　　1. 細胞培養 (Cell Culture) ---------------------------------------------------------- 18
　　2. 細胞存活率實驗 (Cell Viability assay) ─ MTT assay ----------------------- 20
　　3. 西方墨點法 (Western Blot) ------------------------------------------------------ 21
實驗結果 -------------------------------------------------------------------------------------- 23
研究討論 -------------------------------------------------------------------------------------- 26
文獻 -------------------------------------------------------------------------------------------- 28
圖表與說明 ----------------------------------------------------------------------------------- 32

1.104年死因統計結果分析 (2016年版)。台北市：衛生福利部
2.104年各類癌症健保前10大醫療支出統計 (2016年版) 【資料檔】。台北市：中央健康保險署
3.中華民國 103 年癌症登記報告 (2016 年版)。台北市：國民健康署
4.中華民國 93 年癌症登記報告 (2007 年版)。台北市：國民健康署
5.Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136, E359-386, doi:10.1002/ijc.29210 (2015).
6.BW, S. & CP, W. World cancer report 2014.
7.What Is Cancer?, National Cancer Institute. (February 9, 2015)
<https://www.cancer.gov/about-cancer/understanding/what-is-cancer>
8.Arnold, B. et al. Molecular Cell Biology. Sixth edition edn, (W. H. Freeman & Company, 2007).
9.Alberts, B. et al. Molecular Biology of the Cell. Fourth edition edn, (Garland, 2002).
10.Cancer Fact sheet., World Health Organization. (June 10, 2014).
11.Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674, doi:10.1016/j.cell.2011.02.013 (2011).
12.Williams, S. C. No end in sight for telomerase-targeted cancer drugs. Nat Med 19, 6, doi:10.1038/nm0113-6 (2013).
13.Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033, doi:10.1126/science.1160809 (2009).
14.KFSYSCC 2011 annual report. Koo Foundation Sun Yat-Sen Cancer Center (Taiwan).
15.Carey, L., Winer, E., Viale, G., Cameron, D. & Gianni, L. Triple-negative breast cancer: disease entity or title of convenience? Nature reviews. Clinical oncology 7, 683-692, doi:10.1038/nrclinonc.2010.154 (2010).
16.Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N Engl J Med 363, 1938-1948, doi:10.1056/NEJMra1001389 (2010).
17.Arany, I. & Safirstein, R. L. Cisplatin nephrotoxicity. Seminars in nephrology 23, 460-464 (2003).
18.Beyer, J. et al. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Bone marrow transplantation 20, 813-819, doi:10.1038/sj.bmt.1700980 (1997).
19.Hromas, R. et al. Aberrant expression of the myeloid zinc finger gene, MZF-1, is oncogenic. Cancer research 55, 3610-3614 (1995).
20.Perrotti, D. et al. Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Molecular and cellular biology 15, 6075-6087 (1995).
21.Mudduluru, G., Vajkoczy, P. & Allgayer, H. Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Molecular cancer research : MCR 8, 159-169, doi:10.1158/1541-7786.mcr-09-0326 (2010).
22.Hsieh, Y. H. et al. PKCalpha expression regulated by Elk-1 and MZF-1 in human HCC cells. Biochemical and biophysical research communications 339, 217-225, doi:10.1016/j.bbrc.2005.11.015 (2006).
23.Vishwamitra, D. et al. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell lymphoma. Molecular cancer 14, 53, doi:10.1186/s12943-015-0324-2 (2015).
24.Yakar, S. et al. Circulating levels of IGF-1 directly regulate bone growth and density. The Journal of clinical investigation 110, 771-781, doi:10.1172/jci15463 (2002).
25.Arnaldez, F. I. & Helman, L. J. Targeting the insulin growth factor receptor 1. Hematology/oncology clinics of North America 26, 527-542, vii-viii, doi:10.1016/j.hoc.2012.01.004 (2012).
26.Yang, Y. & Yee, D. Targeting insulin and insulin-like growth factor signaling in breast cancer. Journal of mammary gland biology and neoplasia 17, 251-261, doi:10.1007/s10911-012-9268-y (2012).
27.Sarkissyan, S. et al. IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion. PloS one 9, e103534, doi:10.1371/journal.pone.0103534 (2014).
28.Lee, C. J. et al. MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Calpha-based triple-negative breast cancer cells. Oncotarget 7, 59845-59859, doi:10.18632/oncotarget.11337 (2016).
29.Koul, H. K., Pal, M. & Koul, S. Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes & cancer 4, 342-359, doi:10.1177/1947601913507951 (2013).
30.Nogueira, V. et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer cell 14, 458-470, doi:10.1016/j.ccr.2008.11.003 (2008).
31.Farabaugh, S. M., Boone, D. N. & Lee, A. V. Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. Frontiers in endocrinology 6, 59, doi:10.3389/fendo.2015.00059 (2015).
32.Merlin, J. L., Harle, A., Lion, M., Ramacci, C. & Leroux, A. Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins. Oncology reports 30, 1943-1948, doi:10.3892/or.2013.2645 (2013).
33.Antoon, J. W. et al. Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation. Cancer biology & therapy 13, 1026-1033, doi:10.4161/cbt.20992 (2012).